Customizable 3D tumor models and clinical trial materials designed to match your specific cancer type, patient genetics, and drug target — not off-the-shelf compromises.
From sample collection through processing, QC, and delivery — no third-party handoffs, no black boxes. You have full visibility into every step.
US and European laboratory network ensures redundancy, faster turnaround, competitive pricing, and access to tissue types that are scarce in a single market.
DRL provides chain-of-custody, end-to-end traceability, and ethical sourcing that positions this supplier as suitable for IND-ready regulatory work. Clients own their data, models, and IP. No restricted-use licensing surprises.
Study need, indication, biomarkers, endpoints, timelines
Banked/prospective biospecimen collection, QC + metadata
Primary cells, 3D organoids, culture systems
Drug screening, functional assays, omics, biomarker insights
“DRL is committed to procuring high quality human specimens in a timely manner. Their scientists are engaged and proactive at addressing the needs of their clients. We are glad we entrusted DRL with helping us advance our target validation projects and will continue to use their professional services in the future.”
"We prefer to work with DRL for our sample acquisition needs as they provide us with high quality materials in a timely manner. They are agile and able to adapt to our varied needs across projects and requests for different levels of documentation. They respond incredibly quickly and thoroughly to any queries. They complete their collections within projected time frames. Unfortunately for the space as a whole, these observations are in contrast to most vendors. In summary, they are a pleasure to work with and have become my preferred vendor."